1-(m-Methylphenyl)-propanol-2 | 24826-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(m-Methylphenyl)-propanol-2
• 英文别名: (+/-)-2-hydroxy-1-m-tolyl-propane；(+/-)-2-Hydroxy-1-m-tolyl-propan；β-Oxy-α-m-tolyl-propan；3²-Oxy-1-methyl-3-propyl-benzol；Methyl-m-xylyl-carbinol；1-(M-tolyl)propan-2-ol；1-(3-methylphenyl)propan-2-ol
• CAS: 24826-67-3
• 化学式: C₁₀H₁₄O
• 分子量: 150.221
• InChiKey: NDHSAOUBOXJOFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(m-Methylphenyl)-propanol-2 、 苯甲酰氯 在 吡啶 作用下， 生成 benzoic acid-(1-methyl-2-m-tolyl-ethyl ester)
  参考文献：
  名称：

  Carre, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1909, vol. 148, p. 1109

  摘要：

  DOI：
• 作为产物：
  描述：

  1-环己烯乙酮 在 lithium aluminium tetrahydride 作用下， 生成 1-(m-Methylphenyl)-propanol-2
  参考文献：
  名称：

  Photochemistry of cycloalkenes. VI. Intramolecular additions

  摘要：

  DOI：

  10.1021/ja01054a041

文献信息

• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• Visible-Light-Mediated Anti-Markovnikov Hydration of Olefins
  作者：Xia Hu、Guoting Zhang、Faxiang Bu、Aiwen Lei

  DOI：10.1021/acscatal.6b03388

  日期：2017.2.3

  avoided the need for a transition-metal catalyst, stoichiometric borane, as well as oxidant. Both terminal and internal olefins are readily accommodated in this transformation to obtain corresponding primary and secondary alcohols in good yields with single regioselectivity. This procedure can be scaled up to gram scale with a 230 turnover number based on photocatalyst.

  考虑到经典的烯烃抗马尔可夫尼科夫水合过程需要化学计量的硼烷和氧化剂，因此在催化方案中实现转化仍然很有吸引力。本文中，通过使用有机光氧化还原催化剂与氧化还原活性氢原子供体结合使用，可见光介导的反马尔科夫尼科夫水向烯烃的加成反应避免了过渡金属催化剂（化学计量的硼烷）的使用。以及氧化剂。末端烯烃和内部烯烃都易于容纳在该转化中，从而以单一区域选择性以高收率获得相应的伯醇和仲醇。基于光催化剂，该程序可以按230倍的转换规模放大至克级。
• [EN] AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] AMINOBENZIMIDAZOLES ET BENZIMIDAZOLES UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS SYNCYTIAL RESPIRATOIRE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005058869A1

  公开（公告）日：2005-06-30

  Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula (I) the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; wherein G is a direct bond or C1-10alkanediyl optionally substituted with one or more hydroxy, C1-6alkyloxy, Ar1Cl-6alkyloxy, C1-6alkylthio, Ar1C1-6alkylthio, HO(-CH2-CH2-O)n-, C1-6alkyloxy(-CH2-M2-O)n- or Ar1Cl-6alkyloxy(-CH2-C2-O)n-; R1 is Ar1 or a monocyclic or bicyclic heterocycle; Q is hydrogen, amino or mono- or di(C1-4alkyl)amino; one of R2a and R3a is selected from halo, optionally mono- or polysubstituted C1-6alkyl, optionally mono- or polysubstituted C2-6alkenyl, nitro, hydroxy, Ar2, N(R4aR4b), N(R4aR4b)sulfonyl, N(R4aR4b)carbonyl, C1-6alkyloxy, Ar2oxy, Ar2C1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, or -C(=Z)Ar2; and the other one of R2a and R3a is hydrogen; in case R2a is different from hydrogen then R2b is hydrogen, C1-6alkyl or halogen and R3b is hydrogen; in case R3a is different from hydrogen then R3b is hydrogen, C1-6alkyl or halogen and R2b is hydrogen. Compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

  氨基苯并咪唑和对RSV复制具有抑制活性的苯并咪唑，其具有式(I)的前药、N-氧化物、加合盐、季铵盐、金属配合物和立体化学异构体形式；其中G是直接键或C1-10烷二基，可选地取代一个或多个羟基、C1-6烷氧基、Ar1Cl-6烷氧基、C1-6烷基硫氧基、Ar1C1-6烷基硫氧基、HO(-CH2-CH2-O)n-、C1-6烷氧基(-CH2-M2-O)n-或Ar1Cl-6烷氧基(-CH2-C2-O)n-；R1是Ar1或单环或双环杂环；Q是氢、氨基或单或双(C1-4烷基)氨基；R2a和R3a中的一个选择自卤素、可选地单或多取代的C1-6烷基、可选地单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或-C(=Z)Ar2；R2a和R3a中的另一个是氢；如果R2a不同于氢，则R2b是氢、C1-6烷基或卤素，而R3b是氢；如果R3a不同于氢，则R3b是氢、C1-6烷基或卤素，而R2b是氢。含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的方法。
• [EN] COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS<br/>[FR] POLYTHÉRAPIE POUR TRAITER UN PARAMYXOVIRUS
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2016022464A1

  公开（公告）日：2016-02-11

  Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.

  本文披露了一种化合物组合以及使用该化合物组合来改善、治疗和/或预防副黏病毒感染的方法。
• FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170174613A1

  公开（公告）日：2017-06-22

  Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

  提供了制备芬氟拉明活性药物成分的方法。该方法的步骤包括（a）水解2-(3-(三氟甲基)苯基)乙腈组合物，以产生2-(3-(三氟甲基)苯基)乙酸组合物；（b）将2-(3-(三氟甲基)苯基)乙酸组合物与乙酸酐和催化剂反应，以产生1-(3-(三氟甲基)苯基)丙酮组合物；以及（c）使用硼氢化还原剂将1-(3-(三氟甲基)苯基)丙酮组合物与乙胺还原胺化，以产生芬氟拉明组合物。还提供了根据该方法制备的组合物和药用成分，包括芬氟拉明的药用可接受盐，并且在总三氟甲基异构体中的重量不到0.2%。